PFIZER Australia in consultation with the TGA has initiated a recall for product correction for bottles of phenytoin 30mg capsules, 100mg capsules and 50mg tablets which are marketed under the brand name Dilantin.
It has been identified that bottles of the epilepsy medication have been supplied with child-resistant caps that may not engage or otherwise be properly secured.
Pharmacists are being asked to give anyone who has been dispensed Dilantin a copy of a "patient communication letter" and check that child-resistant caps are functioning correctly before dispensing new Dilantin scripts or replacing returned bottles.
The above article was sent to subscribers in Pharmacy Daily's issue from 07 Dec 16
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 07 Dec 16
